Kim has 30 years of experience in accounting and finance, including 25 years in the field of healthcare diagnostic products and services. She is an operations and commercially focused leader who brings a wealth of experience in scaling organizations that bring new technology and services to market.

Prior to joining BrainScope, Kim served as the Chief Financial Officer of private equity-backed Prelude Fertility, a comprehensive fertility services company. During her time there, she led the successful integration of finance and billing operations for multiple acquisitions, establishing Prelude as the fastest growing and largest network of fertility clinics in the country.

Before Prelude, Kim spent five years as the Chief Financial Officer of Boston Heart Diagnostics, a venture-backed CVD diagnostic services start-up. At Boston Heart, Kim was responsible for establishing and scaling all aspects of the company’s financial operations, revenue cycle, commercial support, and HR functions through the successful sale of the company to Eurofins Scientific SE.

Prior to Boston Heart, Kim was the VP Finance at Ipsogen Inc., the US commercial division of French Biotech, Ipsogen S.A., a blood and breast cancer molecular diagnostic product and services company. During her time at Ipsogen, Kim established the Finance function and was responsible for all aspects of Finance and HR operations, and supported the M&A that resulted in the successful sale of the company to Qiagen.

Earlier in her career, Kim was a senior auditor at Ernst & Young LLP, held both accounting and analyst roles at American Cyanamid Company, an international agricultural, chemical, and pharmaceutical conglomerate, and had a 14-year tenure with Quest Diagnostics, a laboratory services company, where she held various roles of increasing responsibility in both Finance and Marketing.

.

Susan is an innovative and successful healthcare executive with over 30 years of diagnostics, products, and services experience. She joined BrainScope in June of 2019.

Most recently, Susan was Chief Executive Officer of private equity-backed Prelude Fertility, a comprehensive fertility services company. In just two years, Susan drove the commercial strategy, built the team, and created the largest and fastest-growing fertility services company in the country with over 28 locations in 14 states. She also completed a first of its kind deal with NYU Langone. Prelude completed a merger with Inception Fertility in April of 2019.  

Prior to joining Prelude, Susan spent more than six years as President and Chief Executive Officer of Boston Heart Diagnostics, a diagnostics services start-up backed Bain Capital Ventures. During her tenure at Boston Heart, the company grew organically from $4M to just under $95M in 5 years, went from 30 to 550 employees, and tested over one million patients. Susan led the successful exit of Boston Heart in January 2015, in a deal valued at just under $200M.

Prior to Boston Heart, Susan was Chief Executive Officer at Ipsogen Inc, a molecular diagnostics company with products focused on blood and breast cancers. In less than 3 years, she built the US into the largest market within Ipsogen and along with the Founder CEO co-led the M&A that resulted in the sale of the company to Qiagen. Susan spent the earlier part of her career at Quest Diagnostics where she held various executive positions including head of marketing, corporate identity, payer contracting, and supply chain and materials management. She also spent time at Abbott Diagnostics and Oxford Health Plans (now part of United Healthcare).

Susan’s deep experience in a variety of diagnostics, provider services, and payer contracting companies have given her a unique perspective on the market. She has successfully anticipated shifting healthcare trends throughout her career and has used this to innovate and drive growth under a variety of conditions.

Susan received an MBA from Columbia University and is an EY “Entrepreneur of the Year.” (2014). She serves on the board of directors of BreastCancer.Org and is a strategic advisor to the Founders Affiliate Board of Directors of the American Heart Association.

Leslie S. Prichep, Ph.D. is the Chief Scientific Officer of BrainScope, where she directs the Company’s scientific research and algorithm development efforts using machine learning and artificial intelligence to identify scientifically-validated biomarkers of traumatic brain injury and concussion. She is also responsible for the scientific integrity of the product.

Dr. Prichep came to BrainScope from a significant academic tenure as a neuroscientist at NYU School of Medicine where she was the Director of the Brain Research Laboratories (BRL) and Professor of Psychiatry. The BrainScope platform has at its core, the technology she co-developed while at BRL and which they licensed from NYU.

Dr. Prichep is highly respected and known as a pioneering innovator in quantitative electrophysiology and clinically applied translational research in a number of brain-related disease states including traumatic brain injury, dementia, addiction, depression, and schizophrenia. Dr. Prichep has over 150 peer-reviewed publications, with another 55 book chapters, books, published proceedings, and monographs, holds a number of patents, and is considered one of the preeminent research scientists in the field of computerized electrophysiological. In recognition of her contribution to neurotechnology development, Dr. Prichep was elected as a Fellow of the National Academy of Inventors in 2019.

Dr. Prichep has been working with BrainScope since its inception in 2006.

Laurie Silver has over 20 years’ experience with a financial, accounting, strategic planning, and operations background. Prior to BrainScope, she served as Director of Mergers and Acquisitions for the Services group at Symantec, where she led the integration of the Services organizations upon the $13 billion merger of Symantec and Veritas, which was the largest software company merger in history. Prior to Symantec, Ms. Silver was the Vice President of Finance and Administration of TrueCareers, a subsidiary of Sallie Mae; Manager of Financial Planning and Analysis across all business units of ABC/Disney; and a Senior Auditor at Ernst & Young LLP in New York. Ms. Silver graduated from the Stephen M. Ross School of Business at the University of Michigan and earned a CPA license from the State of New York. She has been with BrainScope since 2009.

Kent Butler leads the company’s commercial operations for North America. He is driven by a passion to introduce disruptive and new technologies that help advance the standard of care for patients and providers. He joined BrainScope in 2019 with over 15 years of sales and marketing experience and a focus on medical devices. Kent has held a variety of sales management positions most recently as Area Vice President at Vapotherm, where he successfully led a team of sales directors and sales managers from a distributor model to a fully direct team that helped drive company revenue from $7MM annually to over $40MM annually before going public. Prior to Vapotherm, Kent was an Area Sales Director at ConMed Electrosurgery where he and his team were consistently among the company’s top performers. Kent graduated with a Bachelor’s in Business Administration and earned his MBA from Walsh College.

Susan is an innovative and successful healthcare executive with over 30 years of diagnostics, products, and services experience. She joined BrainScope in June of 2019.

Most recently, Susan was Chief Executive Officer of private equity-backed Prelude Fertility, a comprehensive fertility services company. In just two years, Susan drove the commercial strategy, built the team, and created the largest and fastest-growing fertility services company in the country with over 28 locations in 14 states. She also completed a first of its kind deal with NYU Langone. Prelude completed a merger with Inception Fertility in April of 2019.  

Prior to joining Prelude, Susan spent more than six years as President and Chief Executive Officer of Boston Heart Diagnostics, a diagnostics services start-up backed Bain Capital Ventures. During her tenure at Boston Heart, the company grew organically from $4M to just under $95M in 5 years, went from 30 to 550 employees, and tested over one million patients. Susan led the successful exit of Boston Heart in January 2015, in a deal valued at just under $200M.

Prior to Boston Heart, Susan was Chief Executive Officer at Ipsogen Inc, a molecular diagnostics company with products focused on blood and breast cancers. In less than 3 years, she built the US into the largest market within Ipsogen and along with the Founder CEO co-led the M&A that resulted in the sale of the company to Qiagen. Susan spent the earlier part of her career at Quest Diagnostics where she held various executive positions including head of marketing, corporate identity, payer contracting, and supply chain and materials management. She also spent time at Abbott Diagnostics and Oxford Health Plans (now part of United Healthcare).

Susan’s deep experience in a variety of diagnostics, provider services, and payer contracting companies have given her a unique perspective on the market. She has successfully anticipated shifting healthcare trends throughout her career and has used this to innovate and drive growth under a variety of conditions.

Susan received an MBA from Columbia University and is an EY “Entrepreneur of the Year.” (2014). She serves on the board of directors of BreastCancer.Org and is a strategic advisor to the Founders Affiliate Board of Directors of the American Heart Association.

Miles Gilburne has been active for more than 25 years as a venture capitalist, corporate strategist, and technology lawyer. He is currently a managing member of ZG Ventures, an early-stage venture capital firm focused on media, information technology, and health sciences.

Prior to forming ZG Ventures in 2000, Gilburne served for five years as Senior Vice President of Corporate Development for America Online, where he was responsible for strategic planning, corporate acquisitions, joint ventures, and alliances. He was elected to the board of directors of AOL in 1999 and, after the merger of AOL with Time Warner, continued to serve on the board of the combined company until stepping down in May 2006.

Gilburne has been an early investor in or served on the board of a wide variety of public and private companies, including media companies such as AOL, Time Warner, and Cricket Media, technology and government service companies such as Macromedia and SRA, drug development companies such as Pharmacyclics and GlycoFi, and medical device companies such as BrainScope.

Gilburne has also served as a board member of numerous non-profit organizations, including the Board of Trustees of The Shakespeare Theatre in Washington, D.C., and the Foundation for the National Institutes of Health. He received a B.A. from Princeton University and a J.D. from Harvard Law School.

James Peake was United States Secretary of Veterans Affairs from 2007 to 2009. In 2004, he retired from a 42-year United States Army career. He also served as the 40th Surgeon General of the United States Army. Peake received his Bachelor of Science degree from U.S. Military Academy at West Point in 1966 and was commissioned a second lieutenant in the U.S. Army Infantry. He served in Vietnam with the 101st Airborne Division where he was awarded the Silver Star, a Bronze Star with "V" device, and the Purple Heart with oak leaf cluster. Following his service in Vietnam, he attended Cornell University’s Weill Cornell Medical College and was awarded a medical doctorate in 1972. He is also a graduate of the United States Army War College, in 1988. He retired from the Army in 2004, as a Lieutenant General.

Dr. Peake served for four years as the United States Army Surgeon General. He also served as commander of several Army medical units. Previous key assignments include Commander, U.S. Army Medical Department Center and School and Installation Commander, Fort Sam Houston, Texas; Deputy Commander, U.S. Army Medical Command, Fort Sam Houston, Texas; Commanding General, Madigan Army Medical Center/Northwest Health Service Support Activity, Tacoma, Washington; Commanding General, 44th Medical Brigade/Corps Surgeon, XVIII Airborne Corps, Fort Bragg, North Carolina; Deputy Director, Professional Services/Chief, Consultant, Office of the Surgeon General, Falls Church, Virginia; Commander, 18th Medical Command and 121st Evacuation Hospital/Command Surgeon, Seoul, Korea; Deputy Commander for Clinical Services, Tripler Army Medical Center, Honolulu, Hawaii; Assistant Chief, Cardiothoracic Surgery, Brooke Army Medical Center, Fort Sam Houston, Texas; Staff General Surgeon/Chief, General Surgery Clinic, DeWitt Army Hospital, Fort Belvoir, Va.; and General Surgery Resident, Brooke Army Medical Center, Fort Sam Houston, Texas.

After retiring from the Army, Dr. Peake served as Executive Vice President and Chief Operating Officer of Project Hope, a non-profit international health foundation operating in more than 30 countries. While at Project HOPE he helped to orchestrate the use of civilian volunteers aboard the Navy Hospital Ship Mercy as it responded to the Tsunami disaster in Indonesia and also as part of the Hurricane Katrina response aboard the Hospital Ship Comfort.

Cyn­thia Ringo is a Senior Part­ner of DBL Part­ners and a Man­ag­ing Part­ner of a prior fund man­aged under DBL Investors. Cynthia Ringo cur­rently sits on the board of direc­tors of The Real­Real, Urban­sit­ter, Maiyet, RubyRib­bon, Siva Power, and the Bay Area BUILD and is a mem­ber of Wom­en­Cor­po­rate­Di­rec­tors (WCD) Foun­da­tion. She also served on the board of the Forum for Women Entre­pre­neurs from 2000 to 2004, and as Chair of the Board from 2001 through 2003. Ms. Ringo was for­merly a Man­ag­ing Direc­tor of Van­tage­Point Ven­ture Part­ners from 2002 to 2008. Prior to Van­tage­Point Ven­ture Part­ners, she served as the CEO of Cop­per­com, a next-generation net­work switch­ing com­pany, from 1998 to 2001 and was the Chair­man of the Board from 2001 to 2002.

Gail Wilensky is an economist and a senior fellow at Project HOPE, an international health education foundation. She serves as a trustee of the Combined Benefits Fund of the United Mineworkers of America and the National Opinion Research Center, is on the Board of Regents of the Uniformed Services University of the Health Sciences (USUHS), and the Visiting Committee of Harvard Medical and Dental Schools. She recently served as president of the Defense Health Board and chaired their Health care Subcommittee, was a commissioner on the World Health Organization’s Commission on the Social Determinants of Health, and co-chaired the Dept. of Defense Task Force on the Future of Military Health Care.

She is an elected member of the Institute of Medicine and has served two terms on its governing council. She is a former chair of the board of directors of Academy Health, a former trustee of the American Heart Association, and a current or former director of numerous other non-profit organizations. She is also a director on several corporate boards. From 1990-1992, she was Administrator of the Health Care Financing Administration (now known as CMS), directing the Medicare and Medicaid programs. She also served as Deputy Assistant to President (GHW) Bush for Policy Development, advising him on health and welfare issues from 1992-1993.

From 1997-2001, she chaired the Medicare Payment Advisory Commission, which advises Congress on payment and other issues relating to Medicare, and previously chaired one of its predecessor commissions, the Physician Payment Review Commission. From 2001 to 2003, she co-chaired the President’s Task Force to Improve Health Care Delivery for Our Nation’s Veterans and in 2007, served as a Commissioner on the President’s Commission on Care for America’s Returning Wounded Warriors (Dole/Shalala Commission).

Dr. Wilensky testifies frequently before Congressional committees, serves as an advisor to members of Congress and other elected officials, speaks nationally and internationally before professional, business, and consumer groups. She received a bachelor’s degree in psychology and a Ph.D. in economics at the University of Michigan and has received several honorary degrees.